Injectable PLGA Microspheres with LNG

Description: Levonorgestrel (LNG) microspheres encapsulated in PLGA are fabricated to achieve longer duration of hormone release. PLGA with 50:50 and 85:15 lactic acid to glycolic acid copolymer ratios have been studied. An estimated 5 months would be required to deplete the initial drug load with these copolymer ratios.

Product Details

User: Female

Hormonal: Yes

Delivery Method: Injectable

Duration Type: Short-acting

Duration: Five months

  • single injection

Active Pharmaceutical Ingredient (API):
  • levonorgestrel

Inactive material: PLGA

Multipurpose Preventive Technology (MPT): No

Status Details

Developer: Stanford University

Project Phase: Pre-Clinical and Clinical Development

Development Stage: Pre-clinical

Began discovery in: 2013

Active Development: Unknown

Additional Information

  • Manickam S, et al. (2013) Development and characterization of levonorgestrel-encapsulated injectable poly (lactic-co-glycolic) acid microspheres engineered to specific size distributions for controlled longer-term delivery of contraceptives. Contraception. 88(3): 457-8.

Vertical Tabs